Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fractyl Health, Inc. (GUTS – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fractyl Health, Inc. (GUTS)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Fractyl Health, Inc. today and set a price target of $8.00. The company’s shares closed last Thursday at $0.47.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Fractyl Health, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Ionis Pharmaceuticals (IONS)
RBC Capital analyst Luca Issi maintained a Buy rating on Ionis Pharmaceuticals yesterday and set a price target of $95.00. The company’s shares closed last Thursday at $79.18.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ionis Pharmaceuticals with a $94.93 average price target, representing a 18.2% upside. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
Axsome Therapeutics (AXSM)
Cantor Fitzgerald analyst Pete Stavropoulos maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $220.00. The company’s shares closed last Thursday at $161.19.
According to TipRanks.com, Stavropoulos is a 4-star analyst with an average return of
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $221.87, representing a 35.4% upside. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $230.00 price target.
